This site is intended for Healthcare professionals only.

CABG best option of revascularization in diabetes


CABG best option of revascularization in diabetes

Dr.Krishnan Ramanathan, of  University of British Columbia in Vancouver, Canada, and associates in a study assessed the he generalizability of the FREEDOM (Future REvascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multi-vessel Disease) trial in real-world practice among patients with diabetes mellitus and MV-CAD in residents of British Columbia, Canada by evaluating major cardiovascular outcomes in all patients with diabetes who underwent coronary revascularization between 2007 and 2014 (4,661 patients; 2,947 with ACS). The researchers found that in a real-world population of diabetic patients with Multi-Vessel -CAD, CABG was associated with a lower rate of long-term Major Adverse Cardiac and Cerebrovascular event (MACCE) relative to PCI for both acute coronary syndromes (ACS) and stable ischemic heart disease (SIHD).

The researchers in a large population-based database from British Columbia evaluated major cardiovascular outcomes in all diabetic patients who underwent coronary revascularization between 2007 and 2014 (n = 4,661, 2,947 patients with ACS).

They  found that at 30 days after revascularization, the odds ratio for MACCE for ACS patients favored CABG (odds ratio, 0.49; 95 percent confidence interval [CI], 0.34 to 0.71), whereas, among patients with stable ischemic heart disease (SIHD), MACCE was not impacted by revascularization strategy (odds ratio, 1.46; 95 percent CI, 0.71 to 3.01; Pinteraction < 0.01). Over the longer term (median follow-up of 3.3 years), the benefit of CABG over PCI no longer varied by acuity of presentation (hazard ratio for MACCE in ACS and SIHD patients, 0.67 [95 percent CI, 0.55 to 0.81] and 0.55 [95 percent CI, 0.40 to 0.74], respectively; Pinteraction = 0.28).MACCE relative to PCI for both acute coronary syndromes, ACS and stable ischemic heart disease SIHD.

 The authors concluded that in diabetic patients with MV-CAD,  CABG was associated with a lower rate of long-term MACCE relative to PCI for both ACS and SIHD. A well-powered randomized trial of CABG versus PCI in the ACS population is warranted because these patients have been largely excluded from prior trials.

For further reference log on to :

http://www.onlinejacc.org/content/70/24/2995?sso=1&sso_redirect_count=1&access_token=

Source: JACC

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted